Search
Now showing items 1-10 of 12
Treatment with direct-acting antivirals for HCV decreases but does not eliminate the risk of hepatocellular carcinoma.
(Wiley, 2019-01-13)
Abstract
Background & Aims: Data from Europe and North America have been published re‐
garding the risk of developing hepatocellular carcinoma (HCC) after treatment with
direct antiviral agents (DAA). We proposed to ...
Chronic hepatitis C and chronic kidney disease: Advances, limitations and unchartered territories
(Wiley, 2017-01-20)
Over the past few years, treatment options for chronic hepatitis C virus (HCV) infection have evolved dramatically. The current approved interferon-free direct-acting antiviral (DAA) regimens have been shown to be safe and ...
Hepatotoxicity Induced by Coxibs: How Concerned Should We Be?
(Taylor & Francis, 2016-08-26)
Introduction: The selective inhibitors of COX-2, coxibs, are nonsteroidal anti-inflammatory drugs (NSAIDs) that have much better gastrointestinal safety profile as compared with non-selective NSAIDs. In this review, we ...
Isolated Intrapulmonary Vascular Dilatations and the Risk of Developing Hepatopulmonary Syndrome in Liver Transplant Candidates.
(Elsevier, 2017-08-01)
BACKGROUND:
The natural history of intrapulmonary vascular dilations (IPVD) and their impact on patient outcomes in the setting of portal hypertension has only been described in small series.
AIMS:
To assess the ...
Ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin is safe and effective in HCV-infected patients in a real-life cohort from Latin America.
(Wiley, 2017-09-01)
Information about the use of ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin (OBV/PTV/r/DSV ± RBV) in real-clinical practice in Latin America is scarce. We aimed to confirm safety and effectiveness of OBV/PTV/r/DSV ± RBV ...
The Latin American DILI Registry Experience: A Successful Ongoing Collaborative Strategic Initiative.
(MDPI, 2016-02-25)
Drug induced liver injury (DILI) is a rare but well recognized serious adverse reaction. Pre-marketing studies may not detect liver injury, and DILI becomes very often apparent after the drug is launched to the market. ...
Ombitasvir / paritaprevir / ritonavir / dasabuvir ± ribavirina es segura y efectiva en el HCV - infectados pacientes en una vida real cohorte de América Latina .
(Wiley, 2017-03-29)
Information about the use of ombitasvir/paritaprevir/ritonavir/dasabuvir ± ribavirin (OBV/PTV/r/DSV ± RBV) in real-clinical practice in Latin America is scarce. We aimed to confirm safety and effectiveness of OBV/PTV/r/DSV ± RBV ...
Developing multicenter consortia in liver disease in Latin America: Challenges and opportunities.
(Wiley, 2017-06-07)
The development of consortia has been useful for exploring challenging scenarios and uncharted territories in liver disease treatments. Several consortia already developed in the United States and Europe have become key ...
Incidence, risk factors, and outcomes related with neurological events after liver transplantation in adult and pediatric recipients.
(Wiley, 2018-02-07)
Controversy exists whether NE after LT are more frequently observed in children or adults. We aimed to compare the incidence and outcomes for NE after LT in pediatric and adult recipients. A single-center cohort study, ...
A different gut microbiome linked to inflammation found in cirrhotic patients with and without hepatocellular carcinoma.
(Elsevier B.V. ScienceDirect, 2019-04-15)
Abstract
Introduction and aim: A pro-oncogenic intestinal microbiome was observed in murine models; however, no specific microbiome in patients with hepatocellular carcinoma (HCC) has been reported. We aimed to compare ...